UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000012423
Receipt number R000014533
Scientific Title Association between serum HBV markers and the incidence of developing hepatocellular carcinoma in patients with chronic hepatitis B receiving nucleos(t)ide analogues
Date of disclosure of the study information 2013/11/27
Last modified on 2019/08/02 15:41:12

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Association between serum HBV markers and the incidence of developing hepatocellular carcinoma in patients with chronic hepatitis B receiving nucleos(t)ide analogues

Acronym

Association between serum HBV markers and the incidence of developing hepatocellular carcinoma in patients with chronic hepatitis B receiving nucleos(t)ide analogues

Scientific Title

Association between serum HBV markers and the incidence of developing hepatocellular carcinoma in patients with chronic hepatitis B receiving nucleos(t)ide analogues

Scientific Title:Acronym

Association between serum HBV markers and the incidence of developing hepatocellular carcinoma in patients with chronic hepatitis B receiving nucleos(t)ide analogues

Region

Japan


Condition

Condition

chronic hepatitis B

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Antiviral therapy on patients with chronic hepatitis B aims to suppress the incidence of developing hepatocellular carcinoma (HCC), and nucleos(t)de analogues (NAs) have been generally used in Japan. Although NAs exert antiviral effects through inhibition of HBV DNA reverse transcriptase, they have no effect on cccDNA present in hepatocyte nuclei, so the suppressive effects of NAs against HCC development might be inadequate. The aim of this study is to investigate association between serum HBV markers, including HBV DNA, HBs antigen or HB core-related antigen, and the incidence of HCC in patients with chronic hepatitis B receiving NAs.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

the cumulative incidence of hepatocellular carcinoma
decline of HB surface antigen, loss of HB surface antigen
decline of HB core-related antigen
suppression of HBV DNA (<2.6LC/mL)
ALT normalization
HBe antigen seroconversion (applied in patients positive for HBe antigen att baseline)

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

patients with chronic hepatits B treated with nucleos(t)ide analogues for more than 1 year

Key exclusion criteria

under age of 20
coinfection with HCV / HDV / HIV
coexistence with other chronic liver disease
pregnant or breast-feeding women
coexistence with severe disease of other organs, or immunodeficiency
patients found to be inadequate by their doctors

Target sample size

1500


Research contact person

Name of lead principal investigator

1st name Tetsuo
Middle name
Last name Takehara

Organization

Osaka University Graduate School of Medicine

Division name

Department of Gastroenterology and Hepatology

Zip code

565-0871

Address

2-2, Yamadaoka, Suita, Osaka

TEL

06-6879-3621

Email

takehara@gh.med.osaka-u.ac.jp


Public contact

Name of contact person

1st name Ryoko
Middle name
Last name Yamada

Organization

Osaka University Graduate School of Medicine

Division name

Department of Gastroenterology and Hepatology

Zip code

565-0871

Address

2-2, Yamadaoka, Suita City, Osaka

TEL

06-6879-3621

Homepage URL


Email

ryo726@gh.med.osaka-u.ac.jp


Sponsor or person

Institute

Osaka University Graduate School of Medicine,
Department of Gastroenterology and Hepatology

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor

Itami City Hospital
Higashiosaka City Central Hospital
Otemae Hospital
Sumitomo Hospital
Nishinomiya Municipal Central Hospital
National Hospital Organization Osaka National Hospital
Osaka Police Hospital
NTT West Osaka Hospital
Kansai Rosai Hospital
Osaka Koseinenkin Hospital
Yao Municipal Hospital
Suita Municipal Hospital
Ashiya Municipal Hospital
Saiseikai Senri Hospital
Hyogo Prefectural Nishinomiya Hospital
National Hospital Organization Osaka Minami Medical Center
Toyonaka Municipal Hospital
Osaka Medical Center for Cancer and Cardiovascular Diseases
Minoh City Hospital

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Osaka University Clinical Research Review Committee

Address

2-2, Yamadaoka, Suita, Osaka

Tel

06-6210-8289

Email

rinri@hp-crc.med.osaka-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 11 Month 27 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2013 Year 04 Month 11 Day

Date of IRB


Anticipated trial start date

2013 Year 12 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

prospective study / retrospective study


Management information

Registered date

2013 Year 11 Month 27 Day

Last modified on

2019 Year 08 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014533


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name